Optimal strategies for COVID-19 prevention from global evidence achieved through social distancing, stay at home, travel restriction and lockdown: a systematic review
- PMID: 34419145
- PMCID: PMC8380106
- DOI: 10.1186/s13690-021-00663-8
Optimal strategies for COVID-19 prevention from global evidence achieved through social distancing, stay at home, travel restriction and lockdown: a systematic review
Abstract
Background: Coronavirus disease (COVID-19) is a global public health agenda with high level of pandemicity. There is no effective treatment, but prevention strategies can alter the pandemic. However, the effectiveness of existing preventive measures and strategies is inconclusive. Therefore, this study aimed to review evidence related to COVID-19 prevention achieved through social distancing, stay at home, travel ban and lockdown in order to determine best practices.
Methods/design: This review has been conducted in accordance with the PRISMA and Cochrane guideline. A systematic literature search of articles archived from major medical databases (MEDLINE, SCOPUS, CINAHL, PsycINFO, and Web of Science) and Google scholar was done. Observational and modeling researches published to date with information on COVID-19 prevention like social distancing, stay at home, travel ban and lockdown were included. The articles were screened by two experts. Risk of bias of included studies was assessed through ROBINS-I tool and the certainty of evidence was graded using the GRADE approach for the main outcomes. The findings were presented by narration and in tabular form.
Results: A total of 25 studies was included in the review. The studies consistently reported the benefit of social distancing, stay at home, travel restriction and lockdown measures. Mandatory social distancing reduced the daily growth rate by 9.1%, contacts by 7-9 folds, median number of infections by 92% and epidemic resolved in day 90. Travel restriction and lockdown averted 70.5% of exported cases in china and doubling time was increased from 2 to 4 days. It reduced contacts by 80% and decreased the initial R0, and the number of infected individuals decreased by 91.14%. Stay at home was associated with a 48.6 and 59.8% reduction in weekly morbidity and fatality. Obligatory, long term and early initiated programs were more effective.
Conclusion: Social distancing, stay at home, travel restriction and lockdown are effective to COVID-19 prevention. The strategies need to be obligatory, initiated early, implemented in large scale, and for a longer period of time. Combinations of the programs are more effective. However, the income of individuals should be guaranteed and supported.
Keywords: COVID-19; Social distancing; Stay at home; Travel restriction and lockdown.
© 2021. The Author(s).
Conflict of interest statement
The authors declare no conflict of interest with anybody.
Figures
Similar articles
-
Effectiveness of non-pharmaceutical public health interventions against COVID-19: A systematic review and meta-analysis.PLoS One. 2021 Nov 23;16(11):e0260371. doi: 10.1371/journal.pone.0260371. eCollection 2021. PLoS One. 2021. PMID: 34813628 Free PMC article.
-
Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic review.Trop Med Health. 2020 Nov 23;48(1):91. doi: 10.1186/s41182-020-00285-w. Trop Med Health. 2020. PMID: 33292755 Free PMC article. Review.
-
Non-Pharmacologic Interventions in COVID-19 Pandemic Management; a Systematic Review.Arch Acad Emerg Med. 2023 Jul 23;11(1):e52. doi: 10.22037/aaem.v11i1.1828. eCollection 2023. Arch Acad Emerg Med. 2023. PMID: 37671267 Free PMC article. Review.
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
Effectiveness of different types and levels of social distancing measures: a scoping review of global evidence from earlier stage of COVID-19 pandemic.BMJ Open. 2022 Apr 11;12(4):e053938. doi: 10.1136/bmjopen-2021-053938. BMJ Open. 2022. PMID: 35410924 Free PMC article.
Cited by
-
Impact of COVID-19 on Sleep, Anxiety, and Depression Among Medical Call Center Staff: Insights from a January 2021 Study.Med Sci Monit. 2024 Sep 4;30:e945327. doi: 10.12659/MSM.945327. Med Sci Monit. 2024. PMID: 39228111 Free PMC article.
-
The Lancet Commission on lessons for the future from the COVID-19 pandemic.Lancet. 2022 Oct 8;400(10359):1224-1280. doi: 10.1016/S0140-6736(22)01585-9. Epub 2022 Sep 14. Lancet. 2022. PMID: 36115368 Free PMC article. Review. No abstract available.
-
Psychological and psychosocial determinants of COVID related face covering behaviours: A systematic review.Campbell Syst Rev. 2024 Jul 20;20(3):e1422. doi: 10.1002/cl2.1422. eCollection 2024 Sep. Campbell Syst Rev. 2024. PMID: 39035996 Free PMC article. Review.
-
Oral Manifestations in Children Diagnosed with COVID-19: A Narrative Review.Healthcare (Basel). 2023 Jan 17;11(3):288. doi: 10.3390/healthcare11030288. Healthcare (Basel). 2023. PMID: 36766863 Free PMC article. Review.
-
Temporal changes in health-related lifestyle during the COVID-19 epidemic in Finland - a series of cross-sectional surveys.BMC Public Health. 2022 Nov 19;22(1):2130. doi: 10.1186/s12889-022-14574-y. BMC Public Health. 2022. PMID: 36403034 Free PMC article.
References
-
- World Health Organization (WHO). Naming the coronavirus disease (COVID-19) and the virus that causes it”. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technica...
-
- World Health Organization (WHO). Rolling updates on coronavirus diseases (COVID-19). Available from www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-theyha...
-
- Guan W, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
-
- World Health Organization. Novel coronavirus (2019-nCOV). Situation Report 51. 2020 [Available from: https://www.who.int/docs/default-source/ coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62 e57_10.
-
- Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A trial of lopinavir– ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382(19):1787–1799. doi: 10.1056/NEJMoa2001282. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources